

London closed in the red after a mixed opening on Wall Street as banks and miners ran into profit taking. Among the big caps, GlaxoSmithKline was the...


A mixed opening on Wall Street has provided no guidance for a similarly rudderless London market. Among the big caps, GlaxoSmithKline is the best pe...


While the FTSE 100 is becalmed most of the action is taking place in the FTSE 250 today, where a mixed bag of announcements has prompted varied share ...


Shares in cannabis based medicines developer GW Pharmaceuticals hit a new high for the year after favourable verdicts from regulators on its Sativex o...


GW Pharmaceuticals, the developer and manufacturer of a range of new cannabis based medicines, lost money in the second half of its financial year but...


Geoffrey Guy, executive chairman of GW Pharmaceuticals, has sold almost £600,000 of shares in the cannabis-based medicine firm to co-founder Brian Whi...


Experian may sit in the support services sector but its share price - up 80 per cent from last year's low - makes it look more like a bank. At 493p, u...


GW Pharmaceuticals posted its maiden profits for the year as revenue surged on the back of milestone incomes. Pre-tax profit came in at £4m against ...